TABLE 3.
Effect of the interventions on laboratory blood safety parameters including creatinine kinase, liver function, renal function, fasting glucose, and thyroid function over the 8-week treatment period.
| Placebo |
Ezetimibe |
Nutraceutical |
Combination |
|||||
| Week 0 | Week 8 | Week 0 | Week 8 | Week 0 | Week 8 | Week 0 | Week 8 | |
| Creatinine kinase (U/L) | 99 ± 11 | 103 ± 25 | 130 ± 20 | 119 ± 19 | 110 ± 26 | 132 ± 30 | 112 ± 13 | 120 ± 17 |
| ALT (U/L) | 32 ± 4 | 30 ± 3 | 31 ± 4 | 30 ± 3 | 31 ± 6 | 46 ± 12 | 26 ± 4 | 27 ± 5 |
| GGT (U/L) | 43 ± 11 | 40 ± 11 | 33 ± 7 | 30 ± 6 | 30 ± 9 | 38 ± 13 | 27 ± 7 | 26 ± 4 |
| Glucose (mmol/L) | 5.6 ± 0.1 | 5.4 ± 0.3 | 6.0 ± 0.3 | 5.6 ± 0.4 | 5.7 ± 0.3 | 5.2 ± 0.2 | 5.5 ± 0.1 | 5.2 ± 0.1 |
| Creatinine (μmol/L) | 73 ± 5 | 73 ± 5 | 78 ± 4 | 76 ± 3 | 80 ± 5 | 76 ± 4 | 73 ± 5 | 73 ± 5 |
| eGFR (mL/min) | 84 ± 3 | 83 ± 3 | 82 ± 2 | 86 ± 2 | 80 ± 2 | 84 ± 3 | 79 ± 4 | 78 ± 4 |
| Free T4 (pmol/L) | 12 ± 0 | 12 ± 1 | 12 ± 0 | 13 ± 0 | 12 ± 0 | 14 ± 1 | 12 ± 0 | 14 ± 1 |
| TSH (mU/L) | 1.90 ± 0.37 | 2.14 ± 0.63 | 1.97 ± 0.28 | 1.40 ± 0.44 | 2.34 ± 0.57 | 3.75 ± 1.59 | 1.99 ± 0.40 | 1.77 ± 0.47 |
Mean ± SEM. ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; GGT, gamma-glutamyl transferase; T4, thyroxine, TSH, thyroid stimulating hormone.